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Twenty-one  multiresistant  Enterobacter  cloacae  isolates  producing  OXA-48  (n = 10),  CTX-M-15  (n =  7)  or
both  (n =  4) -lactamases  were  detected  in a Spanish  hospital  during  a  1-year  period  (June  2013  to June
2014).  The  isolates  were  also  resistant  to  non--lactam  antimicrobials,  further  complicating  the  ther-
apeutic  options.  Genotyping  of the  isolates  identiﬁed  two  major  clones  (ST74  and  ST66)  that  caused
prolonged  outbreaks  in different  buildings  of the  hospital  as  well  as some  sporadic  isolates  (ST78,  ST45
and  ST295).  Isolates  belonging  to clone  1 (n  =  7)  were  carbapenem-resistant  and  carried  the  blaOXA-48 gene
on  a  conjugative  IncL/M  plasmid  of ca.  65  kb.  Clone  2 isolates  (n =  11)  were  resistant  to  cefepime  and  har-
boured  the  blaCTX-M-15 gene  on an ca.  150-kb,  non-conjugative  plasmid  of the  IncF  group,  co-harbouring
the  qnrB  and  aac(6′)-Ib-cr  genes  encoding  quinolone  resistance.  Four  clone  2 isolates  were  also  resistant
to  carbapenems  owing  to  the  co-production  of OXA-48.  Most  of the  isolates  were  recovered  from  criti-
cally  ill patients  and  were  admitted  to intensive  care  units;  a single  patient  was  transferred  from  another
Spanish  hospital.  Intrahospital  and  interhospital  dissemination  of multiresistant  E.  cloacae  isolates  is of
major  clinical  concern  as  it could  lead  to endemic  nosocomial  situations.
1. Introduction
Enterobacter cloacae is an opportunistic pathogen frequently
involved in nosocomial infections [1]. This enterobacterial species
is intrinsically resistant to  aminopenicillins, amoxicillin/clavulanic
acid (AMC) and cephalosporins of early generations owing to  a
chromosomally encoded AmpC -lactamase. Isolates overproduc-
ing AmpC are also resistant to broad-spectrum cephalosporins.
Furthermore, E. cloacae has the ability to acquire additional
resistance mechanisms, including plasmid-encoded extended-
spectrum -lactamases (ESBLs) and carbapenemases [1]. Pheno-
typic detection of  ESBL production may  be difﬁcult since it can
be masked by overexpression of AmpC. Some E. cloacae isolates
may also exhibit permeability defects due to the absence of porins
or porin mutations, further increasing the minimum inhibitory
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concentrations (MICs) of -lactams and carbapenems, particularly
ertapenem [1].
In  members of the Enterobacteriaceae family, CTX-M-15 and
OXA-48 are among the most common enzymes involved in
resistance to broad-spectrum cephalosporins and carbapenems,
respectively [2,3]. CTX-M-15 is a  class A ESBL encoded by  the
blaCTX-M-15 gene, which has been identiﬁed in plasmids of  vary-
ing size (85–200 kb) and structure, and often belonging to  the
FII incompatibility (Inc) group [4]. OXA-48 is an Ambler class D
carbapenemase that confers resistance to  penicillins and reduced
susceptibility to carbapenems but does not signiﬁcantly hydrol-
yse broad-spectrum cephalosporins [3]. The blaOXA-48 gene has
been almost always located on a  conjugative plasmid of  ca. 62 kb
assigned to the IncL/M group and has been identiﬁed only in
enterobacterial species [5,6]. Both CTX-M-15 and OXA-48 have
been detected in several enterobacterial species, being particularly
frequent in Klebsiella pneumoniae, whilst they are relatively uncom-
mon in  E. cloacae [2,3]. Here we  report the clinical and genetic
features of 21 E. cloacae isolates producing CTX-M-15, OXA-48 or
both, which were mainly recovered from critically ill patients, in  a
Spanish hospital during a  1-year period.
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2. Patients and methods
2.1.  Setting, patients and bacterial isolates
‘Hospital Universitario Central de Asturias’ (HUCA) (Oviedo,
Spain) is a 1100-bed university hospital providing care for a  popu-
lation of ca. 342,000 inhabitants in the Asturias region of northern
Spain. During the 1-year period from June 2013 to June 2014, all
E. cloacae isolates recovered at the hospital (n  =  448) were analysed
phenotypically for production of carbapenemases and ESBLs. A total
of 21 multiresistant isolates, all recovered from different patients,
produced a carbapenemase, an ESBL or both. Most E. cloacae isolates
were obtained from critically ill patients admitted to two  intensive
care units (ICU1 and ICU2) located in different buildings or to other
hospital wards. Relevant features regarding the patients are shown
in Table 1.
2.2.  Susceptibility testing
All  E. cloacae isolates underwent antimicrobial susceptibility
testing by the disc diffusion assay (Becton Dickinson, Sparks, MD).
The MicroScan® system (Neg Combo Panel Type 53; Siemens
Healthcare Diagnostics, Deerﬁeld, IL) was used for determina-
tion of MICs and for bacterial identiﬁcation, and the latter was
conﬁrmed by matrix-assisted laser desorption/ionisation time-of-
ﬂight mass spectrometry (MALDI-TOF/MS) (microﬂexTM; Bruker
Daltonik GmbH, Bremen, Germany). Results of disc diffusion assays
and MICs were interpreted according to Clinical and Laboratory
Standards Institute (CLSI) breakpoints updated in January 2014
[7]. Etest strips (bioMérieux, Marcy-l’Étoile, France) were used for
determining the MICs of ertapenem and imipenem in  those isolates
suspected of carbapenemase production. The Carba NP test recom-
mended for detection of carbapenemases [8] was also performed
for isolates with elevated MICs of ertapenem and imipenem. All
E. cloacae suspected of ESBL production (double-disc synergy test
positive and/or elevated MIC  to  cefepime) were tested with the
cefepime/cefepime +  clavulanic acid (PM/PML) Etest (bioMérieux).
2.3. Identiﬁcation of genes encoding extended-spectrum
ˇ-lactamases and carbapenemases, and plasmid analysis
Genes encoding resistance to broad-spectrum cephalosporins
(blaTEM, blaSHV and blaCTX-M) and carbapenems (blaOXA-48)  were
identiﬁed by PCR ampliﬁcation [5] followed by sequencing.
Transposon Tn1999 (known to carry the blaOXA-48 gene) and
plasmid-mediated quinolone resistance genes [qnrA, qnrB, qnrS
and aac(6′)-Ib-cr] were searched by  PCR ampliﬁcation followed
by sequencing of the obtained products [3,9]. Plasmid DNA was
extracted by the Kado and Liu method [5] and was visualised by
agarose gel electrophoresis.
Plasmid  Inc groups were determined by  PCR-based replicon typ-
ing [5]. Conjugation experiments were performed using as donor
isolates representatives of three antibiotic resistance phenotypes,
namely resistance to carbapenems but susceptibility to cefepime
(Ecl10), resistance to cefepime but susceptibility to carbapenems
(Ecl8 and Ecl9), or resistance to both (Ecl15). A rifampicin-resistant
Escherichia coli J53 strain was used as recipient for conjugation
assays. Transconjugants were selected on eosin–methylene blue
agar (Oxoid, Madrid, Spain) containing rifampicin (100 mg/L) plus
ertapenem (0.5 mg/L) or rifampicin plus ceftriaxone (10 mg/L).
Plasmid DNA extracted from each of the donor E. cloacae and
their transconjugants was transferred to a  nylon membrane and
was then hybridised with probes speciﬁc for the blaCTX-M-15 and
blaOXA-48 genes. Probes were labelled using the PCR DIG Label-
ing Mix  (Roche Applied Science, Penzberg, Germany), followed by
gel extraction with the GFXTM DNA and Gel Band Puriﬁcation Kit
(Amersham Biosciences, Little Chalfont, UK).
2.4. Pulsed-ﬁeld gel electrophoresis (PFGE) analysis
Total DNA from the 21 E. cloacae isolates was digested with
XbaI (Takara Bio Europe, Saint-Germain-en-Laye, France; 30 U,
4 h at 37 ◦C). The generated fragments were separated by  PFGE
using a  CHEF-DR III System (Bio-Rad Laboratories, Hercules, CA)
under the conditions recommended by PulseNet (http://www.
pulsenetinternational.org). Similarity between XbaI proﬁles was
evaluated by the Jaccard’s coefﬁcient (S), and cluster analysis was
performed by the unweighted pair-group method with arithmetic
averages (UPGMA) using the software program MVSP (Multivariate
Statistical Package for PCs; RockWare Inc., Golden, CO).
2.5.  Multilocus sequence typing (MLST)
MLST was  performed for representative isolates with differ-
ent PFGE proﬁles (Ecl10, Ecl3, Ecl9, Ecl8, Ecl21, Ecl5 and Ecl7) as
described previously [10]. The database available at http://pubmlst.
org/ecloacae was  used for assigning sequence types (STs).
3. Results
3.1. Antimicrobial susceptibility and genetic basis for  resistance
to  broad-spectrum cephalosporins and carbapenems
As shown in Table 2, 20 of the 21 E. cloacae isolates were resistant
to cefotaxime and 11 were also resistant to  cefepime. Moreover, 14
isolates displayed intermediate susceptibility or resistance to  car-
bapenems. In addition to  -lactam antibiotics, all E. cloacae isolates
were variably resistant to  other antimicrobial groups, includ-
ing quinolones (nalidixic acid and ciproﬂoxacin), aminoglycosides
(gentamicin and tobramycin) and trimethoprim/sulfamethoxazole.
The  blaCTX-M-15 gene was detected in all isolates resistant
to  cefepime and positive for the PM/PML test (n  =  11), whilst
the blaOXA-48 gene was found in all isolates with elevated MICs
of imipenem and positive for the Carba NP test (n  =  14). Both
blaCTX-M-15 and blaOXA-48 were identiﬁed in  four isolates. Over-
all,  isolates harbouring blaCTX-M-15,  blaOXA-48 or both accounted for
1.6%, 2.2% and 0.9% of the total number of E. cloacae recovered in
HUCA over the 1-year study period (n  =  448).
The genetic location of blaCTX-M-15 and blaOXA-48 was  established
by  plasmid analysis, hybridisation and conjugation experiments. As
shown in Fig. 1A and Table 2, all ESBL-producers carried a plasmid
of ca. 150 kb hybridising with the blaCTX-M-15 probe and belong-
ing to the IncF group. Furthermore, all imipenem-resistant isolates
harboured a  common plasmid of ca. 65 kb  that gave a  positive
hybridisation signal with the blaOXA-48 probe and belonged to the
IncL/M group. Noteworthy, the blaOXA-48 gene was  always identi-
ﬁed in  transposon Tn1999.1.
To  investigate the potential of transfer of the IncF and IncL/M
plasmids carrying the blaCTX-M-15 and blaOXA-48 genes, conjuga-
tion  experiments were performed using Ecl8 and Ecl9 (blaCTX-M-15),
Ecl10 (blaOXA-48) and Ecl15 (blaCTX-M-15 and blaOXA-48)  as donors.
When selection was performed with ertapenem, E. coli transcon-
jugants were readily obtained both from Ecl10 and Ecl15 donor
strains. Three independent E. coli transconjugants analysed from
each mating experiment showed resistance to  ampicillin, AMC
and ertapenem, were positive by PCR for the blaOXA-48 gene and
carried an ca. 65 kb plasmid (Fig. 1A; Table 2). By contrast, no
transconjugants were obtained after three independent conjuga-
tions using Ecl8 and Ecl9 as donors and ceftriaxone as selective
agent, and only two transconjugants after the same number of
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Table  1
Features of the 21 patients infected or colonised by multiresistant Enterobacter cloacae isolates.
Patient Sex/age (years) Hospital unit Admission
diagnosis/colonisation or
infection  type
Sample  origin Date of
isolation
Treatment Outcome
1 M/46 ICU1 Pancreatitis/surgical
wound infection
Wound exudate 25/06/2013 Tobramycin Discharged
2  F/56 ICU1 Lung cancer/pneumonia Lung necropsy 26/06/2013 TZP Died
3  F/77 ICU2 Cardiac surgery/respiratory
colonisation
Tracheobronchial
aspirate
5/07/2013 Untreated Discharged
4  M/19 ICU1 Severe head injury/urinary
tract  infection
Urine  12/08/2013 Ciproﬂoxacin Died
5  M/81 Reanimation Vascular
surgery/respiratory
infection
Tracheobronchial
aspirate
23/12/2013 Ciproﬂoxacin/
gentamicin/meropenem
Died
6 M/81 ICU2 Vascular
surgery/pneumonia
Tracheobronchial
aspirate
26/12/2013 Imipenem Discharged
7  M/76 General surgery Abdominal
surgery/surgical wound
infection
Wound  exudate 27/12/2013 TZP Discharged
8a F/57 Pneumology unit Lung  transplantation
follow-up/respiratory
infection
Sputum 17/01/2014 Amikacin/meropenem Discharged
9  M/41 ICU2 Septic shock/pneumonia Tracheobronchial
aspirate
21/01/2014 Meropenem Discharged
10  F/33 ICU1 H1N1 ﬂu
pneumonia/respiratory
colonisation
Tracheobronchial
aspirate
23/01/2014 Untreatedb Discharged
11  F/53 ICU1 H1N1 ﬂu
pneumonia/respiratory
colonisation
Tracheobronchial
aspirate
27/01/2014 Untreatedb Discharged
12  M/79 Cardiac surgery Cardiac surgery/urinary
tract  infection
Urinec 29/01/2014 SXT Discharged
13  M/36 ICU2 H1N1 ﬂu
pneumonia/pneumonia
Pleural  ﬂuid 11/02/2014 TZP/colistinb Died
14  M/62 Cardiac surgery Cardiac
surgery/asymptomatic
bacteriuria
Urine 17/02/2014 Untreated Discharged
15  F/30 Cardiology Heart
transplantation/surgical
wound infection
Wound exudate 19/02/2014 Colistin/tigecycline Discharged
16  F/61 ICU2 Cardiac surgery/surgical
wound  infection
Wound exudate 17/03/2014 Imipenem Discharged
17  F/66 Internal medicine Respiratory
failure/asymptomatic
bacteriuria
Urine 24/03/2014 Untreated Discharged
18  M/69 Neurology Epileptic attack/urinary
catheter colonisation
Urine  24/04/2014 Untreated Discharged
19  F/92 Maxillofacial
surgery
Maxillofacial
surgery/urinary tract
infection
Urine  29/04/2014 Meropenem Discharged
20  M/66 Cardiac surgery Cardiac surgery/surgical
wound  infection
Wound exudate 13/05/2014 Unknownd Discharged
21  M/79 ICU2 Vascular surgery/catheter
sepsis
Catheter tip 14/05/2014 Imipenem Discharged
ICU, intensive care unit; TZP, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazole.
a Patient transferred from another hospital in a  nearby region, where the E. cloacae infection had already been diagnosed.
b Patients 10, 11 and 13  were treated with oseltamivir.
c Another E. cloacae isolate with a different resistance pattern and not producing extended-spectrum -lactamase (ESBL) or OXA-48 was detected in the same sample.
d The sample from this patient was  collected in a  primary care centre a  few days after have being discharged of the Cardiac Surgery Unit of the hospital. There are  no
treatment data for this patient.
matings and ceftriaxone selection using Ecl15 as donor. Both
Ecl15 transconjugants were resistant to ampicillin, AMC, broad-
spectrum cephalosporins and aminoglycosides, had an elevated
MIC of ciproﬂoxacin and carried two plasmids, one of ca. 150 kb
and the other slightly larger than 65 kb, which hybridised with the
blaCTX-M-15 and blaOXA-48 probes, respectively (Fig.  1A; Table 2). The
latter could have derived from the ca. 65 kb plasmid through acqui-
sition of additional DNA. Taken together, these results strongly
suggest that the ca. 150 kb IncF plasmid carrying blaCTX-M-15 is  not
self-transferable, but it could be mobilised by  the ca. 65 kb plas-
mid though at a rather low frequency. The qnrB and aac(6′)-Ib-cr
genes were detected in the Ecl15 transconjugants as well as in
the  E. cloacae isolates carrying the IncF plasmid, all with decreased
susceptibility to ciproﬂoxacin.
3.2.  Genotyping of the CTX-M-15- and/or OXA-48-producing
Enterobacter cloacae isolates
Typing  of the 21 E. cloacae isolates by PFGE yielded seven pro-
ﬁles (X1–X7) (Fig. 1B). A  dendrogram of similarity based on these
proﬁles revealed two  main clusters of E. cloacae (clusters I and
II) that were strongly associated with the two separate build-
ings of HUCA (Fig. 1C). Cluster I comprised two  proﬁles (X1 and
X5) with seven and one isolates, respectively. A representative X1
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Table 2
Microbiological characteristics of clinical Enterobacter cloacae isolates and their transconjugants.
Isolatea,b Antimicrobial resistance
phenotype
ESBL/CARB
gene
ERT/IPM MIC
(mg/L)
Corresponding
plasmids
PFGE proﬁle/
cluster/buildingc
MLST
Ecl1, Ecl2, Ecl4, Ecl10,
Ecl11,  Ecl17, Ecl18
AMX-AMC-FOX-CTX-ERT-IPM-
NAL-CIP-SXT
blaOXA-48 4/2 65 kbd X1/I/1 ST74
Tc-Ecl10-ERT (1, 2 and 3)  AMX-AMC-ERT blaOXA-48 2/0.5 65 kbd N/A N/A
Ecl3  AMX-AMC-FOX-CTX-GEN-ERT-
IPM-NAL-CIP-SXT
blaOXA-48 3/2 65 kbd X5/I/2 ST78
Ecl6,  Ecl12, Ecl14, Ecl16,
Ecl20
AMX-AMC-FOX-CTX-FEP-GEN-
TOB-NAL-CIPe
blaCTX-M-15 ≤0.5/≤1 150 kbf X2/II/2 ST66
Ecl9  X3/II/2
Ecl8 AMX-AMC-FOX-CTX-FEP-GEN-
TOB-NAL-CIPe-SXT
blaCTX-M-15 ≤0.5/≤1 150 kbf X4/II/1 ST66
Ecl19,  Ecl21 AMX-AMC-FOX-CTX-FEP-ERT-
IPM-GEN-TOB-NAL-CIPe
blaCTX-M-15,
blaOXA-48
4–6/2–4 150 kbf,  65 kbd X2/II/2 ST66
Ecl13,  Ecl15 X3/II/2
Tc-Ecl15-ERT (1, 2 and 3)  AMX-AMC-ERT blaOXA-48 2/0.5 65 kbd N/A N/A
Tc-Ecl15-CRO (1 and 2) AMX-AMC-CTX-FEP-ERT-GEN-
TOB-CIPe
blaCTX-M-15,
blaOXA-48
1/0.38 150 kbf,
>65  kbd
N/A N/A
Ecl5  AMX-AMC-FOX-ERT-IPM-NAL-
CIP-SXT
blaOXA-48 4/4 65 kbd X6/–/1 ST45
Ecl7  AMX-AMC-FOX-CTX-ERT-IPM-
GEN-TOB-NAL-CIP-SXT
blaOXA-48 8/4 65 kbd X7/–/1 ST295
ESBL, extended-spectrum -lactamase; CARB, carbapenemase; MIC, minimum inhibitory concentration; PFGE, pulsed-ﬁeld gel  electrophoresis; MLST, multilocus sequence
type;  AMX, amoxicillin; AMC, amoxicillin/clavulanic acid; FOX, cefoxitin; CTX, cefotaxime; ERT, ertapenem; IPM, imipenem; NAL, nalidixic acid;  CIP, ciproﬂoxacin; SXT,
trimethoprim/sulfamethoxazole; GEN, gentamicin; FEP, cefepime; TOB, tobramycin; CRO, ceftriaxone; N/A, not applicable.
a Enterobacter cloacae (Ecl) isolates with numbers corresponding to patient numbers in Table 1.  Ecl isolates used as donors in conjugation experiments are shown in bold.
Ecl  isolates for which the MLST was  determined are underlined.
b Escherichia coli transconjugants designated with Tc followed by  the E. cloacae donor isolate and the antimicrobial used for selection: ERT (ertapenem) or CRO (ceftriaxone);
the number of transconjugants tested is shown in parenthesis. No transconjugants were obtained for Ecl9 and Ecl8 after selection with CRO.
c See Fig. 1C and text for details.
d IncL/M plasmids.
e Isolates positive for the qnrB and aac(6′)-Ib-cr genes.
f IncF plasmids.
isolate and the X5 isolate belonged to  ST74 and ST78, respectively,
within the same clonal complex (Fig.  1C; Table 2). All  X1 isolates
were recovered in  building 1, which houses the main ICU of the
hospital (ICU1), where ﬁve of them were detected. The remaining
two came from the internal medicine and neurology services. All
isolates within cluster I were resistant to carbapenems owing to
production of OXA-48 and all were also resistant to broad-spectrum
cephalosporins, consistent with overexpression of the chromo-
somal blaampC gene. Cluster II was associated with a  second building
of the hospital encompassing the cardiac and maxillofacial surgery
units and another ICU (ICU2). It included 11 isolates with identical
(X2; 7 isolates) or closely related (X3 and X4, with 3 and 1 isolates,
respectively) proﬁles assigned to ST66, and all except one (Ecl8; X4
proﬁle) were recovered in  building 2 (Fig.  1C; Table 2). Interestingly,
Ecl8 was identiﬁed from a single patient who had been transferred
from a hospital in  the nearby region of Santander, where the E.
cloacae infection had already been diagnosed. Isolates within clus-
ter II were all resistant to broad-spectrum cephalosporins owing
to the production of CTX-M-15, and 4 of the 11 isolates also har-
boured blaOXA-48 and were therefore resistant to  carbapenems. Two
distantly related proﬁles (X6 and X7) were shown by  OXA-48-
producers belonging to  ST45 and ST295, respectively, and found
in building 1 (Fig. 1C; Table 2).
4. Discussion
Enterobacter cloacae isolates producing OXA-48, CTX-M-15 or
both -lactamases emerged as important pathogens in  HUCA,
a general university hospital in northern Spain. In  fact, they
accounted for 4.7% (21/448) of the total E. cloacae isolates recov-
ered over a 1-year period, although they were not previously
reported in this region. Together with some sporadic isolates,
two major clones (ST74 and ST66, falling in two different clus-
ters according to  PFGE analysis) are causing prolonged outbreaks
in separate buildings of the hospital. The ST74 clone consisted of
carbapenem-resistant isolates carrying the blaOXA-48 gene. This is
the ﬁrst outbreak caused by OXA-48-producing E. cloacae reported
in Europe, but a previous outbreak has been noticed in a neona-
tal ICU in Jerusalem [11]. In contrast to that observed here,
isolates from Israel carried a  derivative of the OXA-48 plasmid
that had acquired the blaCTX-M-14 gene. The second clone identi-
ﬁed (ST66) corresponded to blaCTX-M-15-positive isolates with the
ESBL gene located on an ca. 150-kb, non-conjugative plasmid of
the IncF group. Some of them co-harboured the IncL/M plasmid
and co-produced OXA-48. Interestingly, one of the clone 2 iso-
lates was apparently transferred from another hospital located
in a nearby region of Spain, so in  addition to intrahospital dis-
semination, interhospital spread is contributing to the emergence
of CTX-M-15-producing E. cloacae in HUCA. Additional outbreaks
of E. cloacae producing CTX-M-15 have occurred in a  new-
born ICU in Spain as well as in a  children’s hospital in Finland
[12,13].
Noticeably, some isolates belonging to clone 2 also carried the
blaOXA-48 plasmid, which could have been acquired from other OXA-
48-producing Enterobacteriaceae circulating in the hospital [5; our
unpublished results]. This might be in accordance with the high
frequency of dissemination of the blaOXA-48-carrying plasmid as
previously demonstrated [14].
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Fig. 1. Molecular typing and genetic relationships of Enterobacter cloacae isolates producing OXA-48 and CTX-M-15 -lactamases in a Spanish hospital. (A) Plasmid proﬁles
of  representative E. cloacae isolates and their transconjugants. Lanes i and ii, plasmids obtained from Escherichia coli 39R861 (NCTC 50192) and plasmid RP4 used as molecular
size  standards for uncut DNA; lane 1, Ecl9; lane 2, Ecl15; lane 3, Tc-Ecl15-CRO (1); lane 4, Tc-Ecl15-ERT (1); lane 5, Tc-Ecl15-ERT (2); lane 6, Tc-Ecl15-ERT (3); lanes 7,
Ecl10; and lane 8, Tc-Ecl10-ERT (1). Plasmids hybridising with blaCTX-M-15 and blaOXA-48 probes are marked with arrowheads and asterisks, respectively. (B) Pulsed-ﬁeld gel
electrophoresis (PFGE) proﬁles generated from E. cloacae isolates by XbaI digestion. Lane , Lambda Ladder PFG Marker (New England Biolabs, Beverly, MA)  and lane B, DNA
from Salmonella enterica serovar Braenderup H9812 digested with XbaI, both used as size standards. Lane X1, Ecl10; lane X2, Ecl6; lane X3, Ecl9; lane X4, Ecl8; lane X5, Ecl3;
lane  X6, Ecl5; and lane X7, Ecl7. (C) Dendrogram of similarity showing the relatedness between the XbaI proﬁles. Isolates assigned to each proﬁle as well as the hospital
ward and building in which they were collected are shown. Relevant genes and plasmids carried by each isolate are  also indicated. Clusters I and II comprise ST74 (clone
1)/ST78 (positive for blaOXA-48) and ST66 (clone 2, positive for blaCTX-M-15 ± blaOXA-48) isolates, respectively. X, XbaI  proﬁle; ST, sequence type; ICU, intensive care unit; Inc,
incompatibility group; S, Jaccard’s coefﬁcient of similarity.
Occurrence of the qnrB and aac(6′)-Ib-cr genes in enterobac-
terial isolates producing OXA-48 or ESBLs, including some of
the CTX-M-15-producing E. cloacae isolates causing the out-
break in a neonatal unit in  Spain, was previously noticed
[12].
Most  E. cloacae reported in this study were assigned to STs pre-
viously associated with ESBL- and carbapenemase-producers and
considered as high-risk international clones (ST45, ST66, ST74 and
ST78), with the latter two  belonging to the same clonal complex
[10,15]. Noteworthy, none of these clones had been previously
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associated with OXA-48 production. Since phylogenetic studies on
multiresistant E. cloacae have been initiated only recently, further
studies are required to expand the knowledge of these multiresis-
tant bacteria.
Although the number of E. cloacae producing carbapenemases
or  ESBLs has increased in recent years, their real prevalence could
be underestimated because of difﬁculties in  detecting both -
lactamases. In the present study, the Carba NP test proved to  be  very
efﬁcient for accurate identiﬁcation of carbapenemase-producers.
5. Conclusions
Intrahospital and interhospital dissemination of multiresis-
tant E. cloacae isolates producing CTX-M-15, OXA-48 or both
-lactamases is a  cause of concern due to the limited options
remaining for the treatment of affected patients, most with
critical underlying conditions. Interestingly, as observed for K.
pneumoniae, emergence of both broad-spectrum resistance traits
in single E. cloacae isolates corresponds to the transfer of genes
having disseminated from community pathogens into nosocomial
pathogens. Considering that the community reservoir of some
of these resistance traits is  signiﬁcantly growing nowadays, the
likelihood of witnessing an increased number of nosocomial
outbreaks due to multiresistant E. cloacae is very high.
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